Altimmune (ALT) vs Galectin Therapeutics (GALT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Galectin Therapeutics (GALT) has outperformed Altimmune (ALT) over the past year, losing 49.7% versus a loss of 72.3%. Over five years, GALT leads with a +4.7% price change compared with -87.2% for ALT. Galectin Therapeutics is the larger company by market cap ($271.4 million vs $258.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALT | GALT |
|---|---|---|
| Share price | $1.33 | $2.69 |
| Market cap | $258.80M | $271.35M |
| 1-day change | -5.67% | -4.27% |
| YTD return | -63.16% | -35.34% |
| 1-year return | -72.35% | -49.72% |
| 5-year return | -87.24% | +4.67% |
| EPS (TTM) | $-0.71 | $-0.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $41.00K | — |
| Revenue growth (YoY) | +105.00% | — |
| Net income (latest FY) | $-88.09M | $-30.84M |
| Operating margin | -230460.98% | — |
| Net margin | -214860.98% | — |
| 52-week high | $6.44 | $7.13 |
| 52-week low | $1.32 | $2.03 |
| Distance from 52-week high | -79.35% | -62.27% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1127.82% | +308.92% |
| Average volume | 3.91M | 252.31K |
| Shares outstanding | 194.59M | 100.88M |
| Employees | 57 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GALT has outperformed ALT by 22.6 percentage points over the past year.
About Altimmune
ALT stock →Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Galectin Therapeutics
GALT stock →Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
ALT vs GALT FAQ
Which is bigger, Altimmune or Galectin Therapeutics?
Galectin Therapeutics (GALT) is larger, with a market capitalization of $271.35M compared with $258.80M for Altimmune (ALT).
Which stock has performed better over the past year, ALT or GALT?
GALT returned -49.72% over the past 12 months, compared with -72.35% for ALT (price return, excluding dividends). Past performance does not predict future results.
Are Altimmune and Galectin Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.